[1]
A. Homšek, M. Jovanović, B. Miljković, and K. Vučićević, “Assessment of pembrolizumab exposure in different patient subpopulations using pharmacometric simulation”, arhfarm, vol. 72, no. Suppl. 4, pp. S227-S228, Oct. 2022, Accessed: Nov. 19, 2026. Available: https://test.aseestant.ceon.rs/index.php/arhfarm/article/view/38447